PlainPharmaWatch

CMS Open Payments · Program Year 2024

Nvision Biomedical Technologies, Inc.

Nvision Biomedical Technologies, Inc. reported $80,655.11 across General Payments, Research, and Ownership to 141 physicians and teaching hospitals across 141 transactions.

See the rankings → How this is sourced
$80.7K
All-tracks total
141
Transactions
141
Recipients
−$16.7K
General Payments vs PY2023

Nvision Biomedical Technologies, Inc. reported $80,655.11 across all CMS Open Payments tracks (General + Research + Ownership) to 141 physicians and teaching hospitals in Program Year 2024 - ranking #1238 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $80,655.11, averaging $572.02 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer nvision-biomedical-technologies-inc Nvision Biomedical Technologies, Inc.

$80.7K · #1238/1,925 · 0.0% industry · PY2024

  • TOT $80.7K
  • RANK #1238
  • SHARE 0.0%
  • TXN 141
  • RCP 141
  • CAT 4
  • GEN $80.7K
  • ΔGEN −$16.7K
  • TOP1 27.2%
  • PY 2024

Volume peers

Nearest volume peer: Eton Pharmaceuticals, Inc. ($80.6K)

Elekta Limited$81.6KVisionAir Solutions, LLC$81.4KNvision Biomedical Technolog…$80.7KEton Pharmaceuticals, Inc.$80.6KLouisville URS Solutions, LLC$80.5K
All-tracks payment totals near Nvision Biomedical Technologies, Inc. (CMS Open Payments PY2024)

Nvision Biomedical Technologies, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Nvision Biomedical Technologies, Inc.'s CMS-reported General Payments decreased by $16.7K (−17.1%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: NVISION BIOMEDICAL TECHNOLOGIES, INC.PY2023: NVISION BIOMEDICAL TECHNOLOGIES, INC.PY2024: Nvision Biomedical Technologies, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$97.3KPY2024$80.7K
PY2023
$97,348.09
PY2024
$80,655.11

What the Data Shows for Nvision Biomedical Technologies, Inc.

Averaging $572.02 per transaction and $572.02 per recipient, Nvision Biomedical Technologies, Inc.'s Program Year 2024 total comes to $80,655.11 across 141 transactions and 141 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1238 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

77 transactions worth $52.8K make "Royalty or License" the top general-payment category in the 4-category breakdown below, 65.5% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Across 4 types of general payments, Nvision Biomedical Technologies, Inc.'s largest category was "Royalty or License" at $52.8K - 65.5% of General Payments.

Nvision Biomedical Technologies, Inc. reports 4 general-payment categories - the top three are Royalty or License (65.5%), Consulting Fee (22.3%), and Travel and Lodging (9.9%). The remaining 1 category make up 2.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Nvision Biomedical Technologies, Inc. divides its payments

How the reported total splits across payment categories

1. Royalty or License$52.8K2. Consulting Fee$18.0K3. Travel and Lodging$8.0K4. Food and Beverage$1.8K
Payment Type Amount Transactions
Royalty or License $52.8K 77
Consulting Fee $18.0K 10
Travel and Lodging $8.0K 18
Food and Beverage $1.8K 36

Recipient Concentration in General Payments

The five largest recipient relationships account for $52,510.78 (65.1%) of $80,655.11 in this company's General Payments records across 34 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Nvision Biomedical Technologies, Inc.

The five named recipients with the highest reported General Payments from this company

David Yeager$21.9KStephen Obrien$12.1KMica Murdoch$7.2KWalter Strash$6.0KChristopher Happ$5.2K
  1. 1

    David Yeager

    $21,917.56 across 4 reported transactions

  2. 2

    Stephen Obrien

    $12,106.22 across 28 reported transactions

  3. 3

    Mica Murdoch

    $7,203.75 across 6 reported transactions

  4. 4

    Walter Strash

    $6,047.50 across 6 reported transactions

  5. 5

    Christopher Happ

    $5,235.75 across 2 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Nvision Biomedical Technologies, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Nvision Biomedical Technologies, Inc..

Collagen Matrix, Inc

HHI 1290

Daiichi Sankyo Company LTD

HHI 1293

Whip Mix Corporation

HHI 1295

Thea Pharma Inc.

HHI 1298

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Nvision Biomedical Technologies, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Nvision Biomedical Technologies, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.